Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
DR devices today should do more than just provide crystal clear imaging and assist during diagnosis. Hence, the ImageView Software used in DRX Compass offers upgraded cybersecurity
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
New biotechnology product aims to be world's fastest automatic sanitary solution
Subscribe To Our Newsletter & Stay Updated
